Genprex stock more than doubles on very heavy volume after FTD granted for cancer treatment

Shares of Genprex Inc. GNPX, +169.47% skyrocketed 121% connected monolithic measurement successful day trading Monday, aft the cistron therapy institution said its Reqorsa Immunogene Therapy was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration for usage successful operation with Merck & Co. Inc.'s MRK, +0.22% crab attraction Keytruda. Trading measurement exploded to 163.9 cardinal shares, compared with the full-day mean of astir 476,600 shares, and capable to marque the banal the astir actively traded connected large U.S. exchanges. The institution said the FTD is for usage successful patients with histologically confirmed unresectable signifier III oregon IV non-small compartment lung crab (NSCLC) whose illness progressed aft attraction with Keytruda. "This Fast Track Designation is an important measurement successful our efforts to accelerate objective improvement of REQORSA and different validation of the imaginable of REQORSA to dainty the unmet aesculapian request of patients with late-stage NSCLC," said Genprex Chief Executive Rodney Varner. The stock, which closed astatine a adjacent two-year debased of $1.21 arsenic precocious arsenic Dec. 29, has present gained 7.0% implicit the past 3 months, portion the iShares Biotechnology ETF IBB, -0.30% has mislaid 4.6% and the S&P 500 SPX, +0.59% has precocious 9.9%.